A new biotech has risen from the ashes of Novartis’ red-hot $12 billion acquisition of muscular dystrophy specialist Avidity Biosciences. A spinout planned since that deal’s October announcement has now officially debuted as Atrium Therapeutics, with two preclinical cardio candidates in tow.
